1191108-65-2

Upstream product

• 912545-08-5 2,4-bis-benzyloxy-5-isopropenyl-benzoic acid methyl ester 
• 959838-31-4 methyl 5-bromo-2,4-bis(methoxymethoxy)benzoate 
• 98437-43-5 methyl 2-chloro-3,4-dihydroxybenzoate 
• 943519-37-7 2,4-dihydroxy-5-isopropylbenzoic acid methyl ester 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 909870-99-1 5-isopropyl-2,4-bis(methoxymethoxy)benzoic acid 
• 912998-99-3 (1,3-dihydroisoindol-2-yl)-(2,4-dihydroxy-5-isopropylphenyl)methanone 

Relevant academic research and scientific papers

HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS

The present technology provides compounds according to Formula (I) as well as compositions including such compounds useful for the treatment of cancers such as non-small cell lung cancer, bladder cancer, or colon cancer.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (1 ): or a salt, solvate, N-oxide or tautomer thereof; wherein either R1 is R1a and R2 is R2a; or R1 is R1b and R2 is R2b; provided that in each case at least one of R1 and R2 is other than hydrogen; R1a and R2a are the same or different and each is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl wherein the C1-4 alkyl is optionally substituted by C1-2 alkoxy; R1b and R2b are the same or different and are selected from hydrogen, C(O)NR4R5, C(O)R6 and C(O)OR6 where R6 is C1-4 alkyl, R4 and R5 are both C1-4 alkyl, or NR4R5 forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from O, N or S and oxidised forms of N and S, the heterocyclic ring being optionally substituted by one or two C1-4 alkyl groups and/or one or two oxo groups; and R3 is a group (D): wherein the asterisk denotes the point of attachment to the isoindoline ring; but excluding acetic acid 5-acetoxy-4-isopropyl-2-[5-(4-methyl-piperazin-1 -ylmethyl)-1,3- dihydro-isoindole-2-carbonyl]-phenyl ester.